Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors

• Status: Recruiting
• Trial end date: 2024-11-12
• Target enrollment: 0
• Participant gender: All

Summary

A Study to Evaluate Safety and Effectiveness of Nivolumab in Combination With Ipilimumab in Chinese Patients With Previously Treated Late-Stage Cancer

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Ipilimumab; Nivolumab

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

1. Mainland Chinese subjects with advanced or recurrent solid tumors.

2. One prior anti-cancer therapy that did not work or documented refusal to receive chemotherapy or biological therapy.

Exclusion Criteria:

1. Cancer that has spread to the brain or central nervous system unless it has been adequately treated . In addition, either no longer receiving corticosteroids, or on a stable or decreasing dose of no more than 10 mg daily prednisone (or equivalent).

2. Subjects with carcinomatous meningitis

3. Active, known or suspected autoimmune disease or infection

4. Positive blood screen for chronic infection of hepatitis B or hepatitis C (HCV antibody positive unless HCV RNA is negative)

5. Prior immuno-oncology therapy

Other protocol defined inclusion/exclusion criteria could apply